[Interferon alpha in the treatment of chronic myeloid leukemia. Promises, realities, and perspectives].
Steegmann
J L
JL
Servicio Hematología, Hospital de la Princesa, Madrid.
Granados
E
E
Rodríguez-Salvanés
F
F
Casado
L F
LF
Giraldo
P
P
Lavilla
E
E
Gómez-Casares
M T
MT
Fernández-Contreras
E
E
Odriozola
J
J
D000328:Adult; D000465:Algorithms; D014408:Biomarkers, Tumor / Q000032:analysis; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D006410:Hematopoiesis / Q000187:drug effects; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D007155:Immunologic Factors; D016898:Interferon-alpha; D016044:Fusion Proteins, bcr-abl
Interferón alfa en el tratamiento de la leucemia mieloide crónica. Promesas, realidades y perspectivas.